TSLP Antibody

Western Blot Validation in Human Heart (Lane 1) and Human Prostate (Lane 2). Loading: 15 µg of lysates per lane. Antibodies: TSLP orb1240256 (4 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Western Blot Validation of TSLP with Human Recombinant protein. Loading: 30ng of TSLP partial human recombinant protein per lane. Antibodies: TSLP orb1240256 (Lane 1: 0.25 µg/mL, Lane 2: 0.5 µg/mL, Lane 3: 1 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. TLSP partial human recombinant protein: 15kD, the observed bands at 30kD and 45kD are the dimer and trimer, respectively.

Western Blot Validation in Mouse A-20 Cell Line. Loading: 15 µg of lysates per lane. Antibodies: TSLP orb1240256 (A: 0.5 µg/mL, B: 1 µg/mL, C: 2 µg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.

Immunofluorescence Validation of TSLP in Human Brain Tissue. Immunofluorescent analysis of 4% paraformaldehyde-fixed Human Brain Tissue labeling TSLP with orb1240256 at 20 µg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).

Immunohistochemistry Validation of TSLP in Human Brain Tissue. Immunohistochemical analysis of paraffin-embedded Human Brain Tissue using anti-TSLP antibody (orb1240256) at 2.5 µg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4°C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.

Regulated Expression Validation of TSLP in COPD Patients. (Anzalone et al., 2018). (A) shows NHBE cells, in the absence (Lane 2) or presence (Lane 3) of Tiotropium (100 nM), were stimulated with rhIL-17A (20 ng/ml) (n = 3). (B) shows NHBE cells, with ISs from COPD patients untreated (Lane 2 and Lane 3) or treated (Lane 4) with anti-IL-17A antibody (n = 3). (A) and (B) show TSLP expression decreases with the treatment of anti-cholinergic drugs.

Induced Expression Validation of TSLP in Human Corneal Epithelium (Lin et al., 2018). Immunohistochemical images showing theTSLP protein detected by anti-TSLP antibodies in donor corneal tissues without (Control) or after exposure to IL-32 (50 ng/ml) ex vivo; an isotype IgG antibody was used as a negative control. The production of TSLP was increased after IL-32 treatment.

Induced Expression Validation of TSLP in Human Corneal Tissues (Lin et al., 2013). Immunohistochemical images showing TSLP protein detected by anti-TSLP antibodies in ex vivo donor human corneal tissues without (B1) or with exposure to IL-33 (10 ng/mL) (B2). An isotype IgG antibody (B3) was used as a negative control. Magnificaiton 400X. The staining confirms the increased level of TSLP after IL-33 treatment.

Induced Expression Validation of TSLP in Mesenchymal Stromal Cells (MSCs). (Allakhverdi et al., 2013). Immunocytochemical images showing TSLP protein detected by anti-TSLP antibodies in BM-MSCs unstimulated (control) or stimulated with IL-1/TNF or supernatants of activated MCs (MCactSNT). Isotype is used as a negative control. The production of TSLP increased with the stimulated conditions.